The risk of fracture with taking alpha blockers for treating benign prostatic hyperplasia

Journal of Preventive Medicine and Public Health

Volumn 42, Issue 3, 2009, Pages 165-170

  Lee, Joongyub ^a   Choiu, Nam Kyoung ^a,b   Jung, Sun Young ^a   Kim, Ye Jee ^a   Seong, Jong Mi ^a   Oh, Seung June ^a   Park, Byung Joo ^a,b  

^a Department of Preventive Medicine ^*

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Adrenergic alpha antagonist; Adverse drug reactions; Benign prostatic hyperplasia; Case crossover study; Fracture

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; NEUROLEPTIC AGENT; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; ARTICLE; COMORBIDITY; DOSE RESPONSE; FRACTURE; HIGH RISK PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PROSTATE HYPERTROPHY; RISK ASSESSMENT;

EID: 77953665422     PISSN: 19758375     EISSN: None     Source Type: Journal    
DOI: 10.3961/jpmph.2009.42.3.165     Document Type: Article

References (17)

1. Anighi HM, Metter El, Guess HA, Fozzard JL. Natural history of benign prostatic hypeiplasia and risk of prostatectomy. Urobgy 1991; 38(1 Suppl):4-8.
2. Korea National Statistical Office. Korean Census 2005. Daejeon: Korea National Statistical Office [cited 2008 Oct 11]. Available from: URL: http://www.kosis.kr.
3. Lee E, Park MS, Shin C, Lee H, Yoo K, Kim Y, et al. A high risk group for prostatism: A population-based epidemiological study in Korea. Br J Urol 1997; 79(5): 736-741.
4. Stoevelaar HJ, McDonnell J. Changing therapeutic regimens in benign prostatic hypeiplasia Pharmacoecommics 2001; 19(2): 131-153.
5. Han KS, Hong SJ, Chung BH. Changing trends in the management of benign prostatic hyperplasia during recent 5 years. Korean J Urol 2005; 46(5): 458462.
6. AUA Practice Guidelines Committee. Guideline on the management of benign prostatic hyperplasia. J Urol2003; 170(2 Pt 1): 530-547.
7. Djavan B, Chappie C, Milani S, Marberger M. State of the art on the efficacy and tolerability of ihe alphal-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia J Urol 2004; 64(6): 1081-1088.
8. Maclure M. 'Why me?' versus 'why now?'-differences between operational hypothesis in case control versus case-crossover studies. Pharmacoepidemiol Drug Scf 2001; 16(8): 850-853.
9. Chrischilles E, Rubenstein L, Chao J, Kreder KJ, Gilden D, Shah H. Initiation of nonselecn've alphal antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia A retrospective cohort study. Clin Ther2001; 23(5): 727-743.
10. Souverein PC, Van Staa TP, Egberts AC, De la Rosette JJ, Cooper C, Leufkens HG. Use of alpha blockers and the risk of hip/femur fractures. J Intern Med X2003; 254(6): 548-554.
11. McMahon AD, Evans JM, McGilchrist MM, McDevitt DG, MacDonald TM. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Safl998; 7(4): 275-280.
12. Maclure M. The case-crossover design: A method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133(2): 144-153.
13. McConnell JD, Roehrbom CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride,and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349(25): 2387-2398.
14. Hartikainen S, Lonnroos E, Louhivuori K. Medication as a risk factor for falls: Critical systematic review. J Gerontol A Biol Sci Med Sci 2007; 62(10): 1172-1181.
15. Macdonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: A systematic review of efficacy and adverse effects. BJU Int 2004; 94(9): 1263-1270.
16. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia latest update on al-adrenoceptor antagonists. BJU Int 2005; 95 Suppl 4:29-36.
17. Hall GC, McMahon AD. Comparative study of modified release alpha blocker exposure in elderly patients with fractures. Pharmacoepidemiol Drug Saf 2007; 16(8): 901-907.